Positioning no disclosures inside 60 days, left as found
Options put/call open interest 1.55, read 2026-11-05
Ethical passes the values gate
Price155.94 USD
Fair value267.28
Ethical score70.0/100
Value readUndervaluedas of 6 Nov 2026
Our investment reviews on this name
2026-10-11Read Distribution254.07-38.6% to today ✓Markup gives way to Distribution first Distribution read since August
2026-09-21Read Markup247.51-37.0% to today Distribution gives way to Markup after a 15% rise in 4 weeks
2026-08-21Read Distribution216.12-27.8% to today ✓Accumulation gives way to Distribution after a 24% slide in 7 weeks
2026-07-02Read Accumulation282.85-44.9% to today First review on file: Accumulation
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Alnylam Pharmaceuticals Inc holds its Distribution at $155.94. The statistical read favours the buyers, held for 1 days.
As held on the ledger · 2026-11-06
Phase
Distribution · caution
Quantitative state
The statistical read favours the buyers, held for 1 days
Price at the screen
$155.94
Valuation
8.08 trailing · 14.34 forward price to earnings
Values screen
PASS· score 70.0
Beta
0.44
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
25.74%
Below 33%
Interest-bearing debt is just 25.7% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
25.19%
Below 33%
Cash held in interest-bearing accounts and securities is 25.2% of assets, under the one-third limit.
Pass
Receivables
49.03%
Below 49%
Money owed to the company is 49.0% of assets, under the 49% limit.
Pass
Revenue purity
3.00%
Below 5%
Only 3.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
Alnylam Pharmaceuticals clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 26%, inside the ~33% line, and interest is about 3% of its income, under the ~5% line, so it passes.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when ALNY's ethical verdict changes
Today ALNY passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Undervalued vs our fair value, as of 6 Nov 2026: it trades at roughly a 41% discount to our $267.28 fair value, narrow competitive moat, 16.70% revenue growth.
Fair value range in USD, drawn from the 2026-11-06 screen. The gold marker is the market price at the same screen. A 41.7% discount to the base estimate.
Where our models see it going: fair-value estimate $267.28, with a range of $164.67 to $307.38, dated to the 2026-11-06 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Gene Silencing Drugs Face Narrow Moat Limits
Picture a treatment that turns off faulty genes before they trigger rare diseases. Alnylam has turned that idea into products such as ONPATTRO and AMVUTTRA, driving 96% revenue growth and a 90% return on equity. Yet the opportunity rating sits at none, so we pass despite a 35% gap between the $267 share price and our $360 fair value.
Forward earnings sit at 20 times, margins have reached 13%, and the narrow moat reflects real but limited protection in a crowded rare-disease field. Analyst targets cluster around $425 on a buy consensus, yet those forecasts rest on execution that remains unproven at scale.
The main risks are clinical setbacks, pricing pressure, and competition that could erode the current returns quickly. Currency and regulatory shifts add further volatility for a company still scaling commercial reach. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
ALNY trades on NASDAQ. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-05Distribution$161.08-30.7%Entry 19
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 30.7% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 3%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (25 analysts) rates it buy, with a mean price target of $439.
2026-10-29Distribution$232.40-0.4%Entry 18
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.4% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 3%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (25 analysts) rates it buy, with a mean price target of $439. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-28Distribution$233.29+0.0%Entry 17
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 3%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (25 analysts) rates it buy, with a mean price target of $439. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-27Distribution$233.29+0.0%Entry 16
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 3%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (25 analysts) rates it buy, with a mean price target of $439. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-26Distribution$233.29+0.0%Entry 15
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 3%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (25 analysts) rates it buy, with a mean price target of $439. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-25Distribution$233.29+0.0%Entry 14
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 3%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (25 analysts) rates it buy, with a mean price target of $439. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-24Distribution$233.29+0.0%Entry 13
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 3%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (25 analysts) rates it buy, with a mean price target of $439. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-23Distribution$233.29+0.0%Entry 12
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 3%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (25 analysts) rates it buy, with a mean price target of $439. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-22Distribution$233.29-0.3%Entry 11
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.3% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 3%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (25 analysts) rates it buy, with a mean price target of $439. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-18Distribution$234.03-7.9%Entry 10
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 7.9% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 3%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (25 analysts) rates it buy, with a mean price target of $439.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
